Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

S Shyam Sunder, UC Sharma… - Signal transduction and …, 2023‏ - nature.com
Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

Management of common clinical problems experienced by survivors of cancer

J Emery, P Butow, J Lai-Kwon, L Nekhlyudov… - The Lancet, 2022‏ - thelancet.com
Improvements in early detection and treatment have led to a growing prevalence of survivors
of cancer worldwide. Models of care fail to address adequately the breadth of physical …

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …

AR Lyon, T López-Fernández, LS Couch… - European Heart …, 2022‏ - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools …

AR Lyon, S Dent, S Stanway, H Earl… - European journal of …, 2020‏ - Wiley Online Library
This position statement from the Heart Failure Association of the European Society of
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio …

Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia

J Herrmann - Nature Reviews Cardiology, 2020‏ - nature.com
Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the H eart F ailure A ssociation (HFA), the E …

J Čelutkienė, R Pudil… - European journal of …, 2020‏ - Wiley Online Library
Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection
of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position …

Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association

LS Mehta, KE Watson, A Barac, TM Beckie, V Bittner… - Circulation, 2018‏ - ahajournals.org
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many
people perceive breast cancer to be the number one threat to women's health. CVD and …

Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1

HM Chang, R Moudgil, T Scarabelli… - Journal of the American …, 2017‏ - jacc.org
Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …

Cardiovascular disease in women: clinical perspectives

M Garcia, SL Mulvagh, CN Bairey Merz… - Circulation …, 2016‏ - ahajournals.org
Cardiovascular disease continues to be the leading cause of death among women in the
United States, accounting for≈ 1 of every 3 female deaths. Sex-specific data focused on …

Cardio-Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council

P Lancellotti, TM Suter, T Lopez-Fernandez… - European heart …, 2019‏ - academic.oup.com
Aims Anticancer therapies have extended the lives of millions of patients with malignancies,
but for some this benefit is tempered by adverse cardiovascular (CV) effects. Cardiotoxicity …